MedTrace Logo

New Protein Biomarkers and Technology for Improving Diagnosis and Outcome Prediction in Mild TBI

NCT06327776 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2024-03-25

No results posted yet for this study

Summary

Mild traumatic brain injury(mTBI) is a common cause of consultation to the emergency rooms worldwide and is the most common form of traumatic brain injury. Though classified as mild, as many as 40% of patients suffering mTBI do not make complete recoveries or present persistent symptoms. The present study is intended to determine long term outcome of patients suffering mTBI and to establish new prognostic models with the use of serum and saliva based biomarkers. For this purpose this study will not exclude patients regarding their comorbidities.

Conditions

  • Mild Traumatic Brain Injury

Interventions

OTHER

Serum and saliva biomarkers

2x5mL blood samples and saliva samples will be used to determine the performance of different blood based and saliva biomarkers for determining diagnostic management and prognosis in mTBI patients.

Sponsors & Collaborators

  • Hospital Universitario 12 de Octubre

    lead OTHER

Eligibility

Min Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-04
Primary Completion
2025-07-31
Completion
2025-12-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06327776 on ClinicalTrials.gov